Ethinylestradiol/Drospirenone A Review of its Use as an Oral Contraceptive

[1]  I. Persson,et al.  Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? , 2002, Acta obstetricia et gynecologica Scandinavica.

[2]  D. Skegg.  Evaluating the safety of medicines, with particular reference to contraception , 2001, Statistics in medicine.

[3]  L. Borgelt-Hansen.  Oral contraceptives: an update on health benefits and risks. , 2001, Journal of the American Pharmaceutical Association.

[4]  H. Kuhl.  [New gestagens--advantages and disadvantages]. , 2001, Therapeutische Umschau. Revue therapeutique.

[5]  J. Foidart,et al.  Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 μg ethinylestradiol to healthy lactating women , 2001, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[6]  J. Foidart,et al.  Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. , 2001, Fertility and sterility.

[7]  Candace S. Brown,et al.  Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. , 2001, Journal of women's health & gender-based medicine.

[8]  J. Vandenbroucke,et al.  Oral contraceptives and the risk of venous thrombosis. , 2001, The New England journal of medicine.

[9]  H. Skarabis,et al.  The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[10]  D. Mansour.  Yasmin — a New Oral Contraceptive, a New Progestogen: The Reasons Why , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[11]  W. Oelkers.  Drospirenone — a New Progestogen With Antimineralocorticoid Activity, Resembling Natural Progesterone , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[12]  R. Farmer,et al.  Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database , 2000, BMJ : British Medical Journal.

[13]  R Krattenmacher,et al.  Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. , 2000, Contraception.

[14]  R D Farmer,et al.  A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. , 2000, British journal of clinical pharmacology.

[15]  E. MacGregor,et al.  The Place of Combined Oral Contraceptives in Contraception , 2000, Cephalalgia : an international journal of headache.

[16]  J. Foidart,et al.  A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[17]  A. Pong,et al.  An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. , 2000, Contraception.

[18]  W. Oelkers,et al.  Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers , 2000, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[19]  J. Foidart,et al.  Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[20]  G. Röll,et al.  A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[21]  K. Thomas,et al.  Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[22]  J. Collins,et al.  Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. , 1999, Human reproduction update.

[23]  Spitzer Wo.  Interpretations. The aftermath of a pill scare: regression to reassurance , 1999 .

[24]  B J Oddens,et al.  Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. , 1999, Contraception.

[25]  C. Egarter,et al.  Low dose oral contraceptives and quality of life. , 1999, Contraception.

[26]  I. Thorneycroft.  Cycle control with oral contraceptives: A review of the literature. , 1999, American journal of obstetrics and gynecology.

[27]  M. Lewis.  The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. , 1998, American journal of obstetrics and gynecology.

[28]  M. Rosenberg,et al.  Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. , 1998, American journal of obstetrics and gynecology.

[29]  L. Shulman,et al.  Oral contraceptive practice guidelines. , 1998, Contraception.

[30]  G. Huggins,et al.  Developments in contraception: a comprehensive review of Desogen (desogestrel and ethinyl estradiol). , 1998, Contraception.

[31]  A. Walker,et al.  Newer oral contraceptives and the risk of venous thromboembolism. , 1998, Contraception.

[32]  A. Chandra,et al.  Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. , 1997, Vital and health statistics. Series 23, Data from the National Survey of Family Growth.

[33]  E. Slater,et al.  The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. , 1996, Contraception.

[34]  P. Hannaford,et al.  Evidence-guided prescribing of combined oral contraceptives: consensus statement. An International Workshop at Mottram Hall, Wilmslow, U.K., March, 1996. , 1996, Contraception.

[35]  U. Koch,et al.  Attitudes to current oral contraceptive use and future developments: the women's perspective. , 1996, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[36]  W. Oelkers.  Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure , 1996, Steroids.

[37]  Catherine M Stevens,et al.  Smoking and cycle control among oral contraceptive users. , 1996, American journal of obstetrics and gynecology.

[38]  U. Müller,et al.  A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. , 1996, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[39]  J. Endrikat,et al.  A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. , 1995, Contraception.

[40]  J. Foidart,et al.  Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. , 1995, The Journal of clinical endocrinology and metabolism.

[41]  U. Fuhrmann,et al.  Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity , 1995, Annals of the New York Academy of Sciences.

[42]  S. Long,et al.  Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. , 1995, The Journal of reproductive medicine.

[43]  S. Bagshaw.  The Combined Oral Contraceptive , 1995, Drug safety.

[44]  T. Staks,et al.  Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. , 1993, Contraception.

[45]  L. Dibbelt,et al.  Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. , 1993, Contraception.

[46]  A. Decherney,et al.  EVALUATION OF A NEW GENERATION OF ORAL CONTRACEPTIVES , 1993, Obstetrics and gynecology.

[47]  M. Rosenberg,et al.  Oral contraceptives and cycle control: A critical review of the literature , 1992, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[48]  B. Hazard,et al.  Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. , 1991, The Journal of clinical endocrinology and metabolism.

[49]  D. Back,et al.  The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. , 1991, Contraception.

[50]  G. Voortman,et al.  Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. , 1990, American journal of obstetrics and gynecology.

[51]  R. Derman,et al.  Oral contraceptives and cardiovascular risk: Taking a safe course of action , 1990 .

[52]  R A Hatcher,et al.  A guide to interpreting contraceptive efficacy studies. , 1990, Obstetrics and gynecology.

[53]  J. Brown,et al.  THE RENIN–ANGIOTENSIN SYSTEM AND TOTAL BODY SODIUM AND POTASSIUM IN HYPERTENSIVE WOMEN TAKING OESTROGEN–PROGESTAGEN ORAL CONTRACEPTIVES , 1983, Clinical endocrinology.

[54]  T C Chalmers,et al.  A method for assessing the quality of a randomized control trial. , 1981, Controlled clinical trials.

[55]  R. Taylor,et al.  The Pearl Pregnancy Index reexamined: still useful for clinical trials of contraceptives. , 1981, American journal of obstetrics and gynecology.

[56]  M. G. Crane,et al.  Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin‐aldosterone system , 1978, The American journal of the medical sciences.

[57]  K. Nygren,et al.  Ethinyl estradiol in human milk and plasma after oral administration. , 1978, Contraception.

[58]  W. Oelkers,et al.  Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. , 1976, The Journal of clinical endocrinology and metabolism.

[59]  D. Adams,et al.  Renal Blood Flow and Its Response to Angiotensin II: An Interaction between Oral Contraceptive Agents, Sodium Intake, and the Renin‐Angiotensin System in Healthy Young Women , 1976, Circulation research.

[60]  S. Oparil,et al.  Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity. , 1975, Clinical science and molecular medicine.

[61]  C. Tietze,et al.  Statistical evaluation of contraceptive methods. , 1974, Clinical obstetrics and gynecology.

[62]  G. Nokes,et al.  Effects of oral contraceptives on the renin-angiotensin system and on blood pressure of normal young women. , 1973, The Johns Hopkins medical journal.

[63]  J. Sundsfjord,et al.  Plasma angiotensin II and aldosterone excretion during the menstrual cycle. , 1970, Acta endocrinologica.

[64]  E. M. Symonds,et al.  Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration and substrate. , 1969, Clinical science.

[65]  J. Laragh,et al.  Oral Contraceptives: Renin, Aldosterone, and High Blood Pressure , 1967 .

[66]  R. Landau,et al.  Inhibition of the sodium-retaining influence of aldosterone by progesterone. , 1958, The Journal of clinical endocrinology and metabolism.

[67]  Candace S. Brown,et al.  A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. , 2002, The Journal of reproductive medicine.

[68]  M. Dolker,et al.  International clinical experience with a new low-dose, Monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg , 1999 .

[69]  P. Darney.  OC practice guidelines: minimizing side effects. , 1997, International journal of fertility and women's medicine.

[70]  K. Fotherby,et al.  New progestogens in oral contraception. , 1994, Contraception.

[71]  L. Dibbelt,et al.  Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months. , 1991, Contraception.

[72]  W. Losert,et al.  Progestogens with antimineralocorticoid activity. , 1985, Arzneimittel-Forschung.

[73]  F Murad,et al.  Estrogens and progestins. , 1975 .

[74]  Derek Llewellyn-Jones,et al.  Fundamentals of Obstetrics and Gynaecology , 1982 .